Connect Biopharma Holdings Ltd (CNTB) Stock Price & Analysis
Connect Biopharma Holdings Ltd (CNTB) fell 3.64% to USD 2.12 as of June 10, 2026 at 07:35 UTC, according to Nexqual real-time market data.
CNTB last closed at USD 2.2; the session ranged USD 2.07–2.29 on volume of 339,262 shares. Market capitalization is $133.48M, with a 52-week range of USD 0.78–3.82 (NGM). Source: Nexqual, June 10, 2026 at 07:35 UTC.
Key Statistics (as of June 10, 2026 at 07:35 UTC)
| Price | USD 2.12 |
|---|---|
| Change | ▼ 3.64% (down) |
| Previous Close | USD 2.2 |
| Open | USD 2.23 |
| Day Range | USD 2.07 – 2.29 |
| 52-Week Range | USD 0.78 – 3.82 |
| Volume | 339,262 shares |
| Market Cap | $133.48M |
| Exchange | NGM |
Technical Analysis (CNTB)
Nexqual's technical model rates CNTB "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:35 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.56 (neutral) |
| vs SMA50 | Below (USD 2.55) |
| MACD | -0.09 (negative) |
Analyst Ratings (CNTB)
Wall Street analysts rate CNTB "Strong Buy" based on 7 analysts, with a mean price target of USD 7.07 (range USD 4–10), per Nexqual as of June 10, 2026 at 07:35 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 7.07 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (CNTB)
| EPS Estimate | USD -0.31 |
|---|---|
| Revenue Estimate | $194,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.27 vs est -0.3 ▲ beat |
| 2025-09-30 | USD -0.31 vs est -0.24 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:35 UTC.
Financials & Fundamentals (CNTB)
| Total Revenue | $233,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -11601.78% |
| Profit Margin | +0.00% |
| ROE | -102.94% |
| Debt / Equity | 1.63 |
| Current Ratio | 3.23 |
| Total Cash | $46.03M |
| Total Debt | $693,000 |
| Free Cash Flow | $-33.88M |
Source: Nexqual, June 10, 2026 at 07:35 UTC.
Financial Health Score (CNTB)
Nexqual rates Connect Biopharma Holdings Ltd's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:35 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $46M cash, no debt |
| Cash Flow | Weak — FCF negative: -$34M, burning cash |
| Efficiency | Critical — ROE -103%, ROA -54.2% |
Ownership (CNTB)
| Insider Ownership | +31.82% |
|---|---|
| Institutional Ownership | +54.26% |
| Shares Outstanding | 62.96M |
| Float | 18.86M |
| Short % of Float | +2.63% |
Source: Nexqual, June 10, 2026 at 07:35 UTC.
Leadership (CNTB)
Connect Biopharma Holdings Ltd is led by Barry D. Quart Pharm.D. (age 68), CEO & Director, per Nexqual as of June 10, 2026 at 07:35 UTC.
| CEO & Director | Barry D. Quart Pharm.D. (age 68) |
|---|---|
| President | David L. Szekeres (age 51) |
| Senior Vice President of Finance | Lisa Peraza (age 48) |
| Vice President of Human Resources | Sean T. Ristine (age 55) |
| Senior Vice President of Clinical Development(Consultant) | Srikanth Pendyala |
Major Backers & Investors (CNTB)
Notable institutional backers of Connect Biopharma Holdings Ltd include Ikarian Capital, LLC, Boothbay Fund Management, LLC, 683 Capital Management LLC, according to Nexqual as of June 10, 2026 at 07:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 8.56% |
| Boothbay Fund Management, LLC | 1.96% |
| 683 Capital Management LLC | 1.43% |
| Perceptive Advisors Llc | 1.26% |
| Adar1 Capital Management, LLC | 1.18% |
| Richmond Brothers, Inc. | 0.76% |
| Millennium Management | 0.75% |
| BML Capital Management, LLC | 0.65% |
Source: Nexqual, June 10, 2026 at 07:35 UTC.
From Connect Biopharma Holdings Ltd's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secrets and know-how relating to our proprietary technology and Product Candidates, and we may in the future rely on in-licensing opportunities, to develop, strengthen and maintain our proprietary position in our field.
- Regulation of Drugs and Biologics In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA"), and its implementing regulations, and biologics under the FDCA and the Public Health Service Act, and its implementing regulations.
- Intellectual Property We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including by seeking, maintaining, enforcing and defending patent rights.
- We may file patents containing claims for protection of all useful applications of our proprietary Product Candidates, as well as all new applications and/or uses we discover for existing Product Candidates, assuming these are strategically valuable.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADAG | Adagene Inc. | USD 3.4 | ▲ 2.41% |
| FNCHQ | Finch Therapeutics Group, Inc. | USD 7.45 | ▲ 0% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| ALGS | Aligos Therapeutics, Inc. | USD 5.14 | ▲ 4.68% |
| UNCY | Unicycive Therapeutics, Inc. | USD 7.27 | ▲ 5.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:35 UTC. This page is informational and not investment advice.